Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:627674.
doi: 10.1155/2015/627674. Epub 2015 Aug 31.

Anti-VEGF Therapy and the Retina: An Update

Vikas Tah  1 , Harry O Orlans  2 , Jonathan Hyer  2 , Edward Casswell  2 , Nizar Din  2 , Vishnu Sri Shanmuganathan  3 , Louise Ramskold  2 , Saruban Pasu  2
Affiliations
Review

Anti-VEGF Therapy and the Retina: An Update

Vikas Tah et al. J Ophthalmol. 2015.

Abstract

Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients.

PubMed Disclaimer

References

    1. Rajappa M., Saxena P., Kaur J. Ocular angiogenesis: mechanisms and recent advances in therapy. Advances in Clinical Chemistry. 2010;50:103–121. doi: 10.1016/s0065-2423(10)50006-4. - DOI - PubMed
    1. PMLive. Top Pharma list. November 2014, http://www.pmlive.com/top_pharma_list/Top_50_pharmaceutical_products_by_....
    1. Arroyo J. G. Towards a rational approach to combination therapy for neovascular age related macular degeneration. The British Journal of Ophthalmology. 2007;91(2):130–131. doi: 10.1136/bjo.2006.106534. - DOI - PMC - PubMed
    1. Miller J. W., Adamis A. P., Shima D. T., et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. American Journal of Pathology. 1994;145(3):574–584. - PMC - PubMed
    1. Aiello L. P., Avery R. L., Arrigg P. G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. The New England Journal of Medicine. 1994;331(22):1480–1487. doi: 10.1056/nejm199412013312203. - DOI - PubMed

LinkOut - more resources